To include your compound in the COVID-19 Resource Center, submit it here.

X-396: Phase III started

Xcovery began the open-label, U.S. Phase III eXalt3 trial to compare 225

Read the full 129 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE